ISSN 2415-3060 (print), ISSN 2522-4972 (online)
JMBS
  • 1 of 49
Up
JMBS 2019, 4(4): 8–13
https://doi.org/10.26693/jmbs04.04.008
Medicine. Reviews

Diagnosis and Prevention of Metabolic Syndrome in Combination with Chronic Obstructive Lung Disease

Ziuzin V.1, Cherno V.2, Laricheva O.1, Polovenko L.2, Ziuzin D.V.1
Abstract

The article highlights the diagnosis and prevention of a metabolic syndrome, combined with chronic obstructive pulmonary disease. The questions of the occurrence of metabolic syndrome, the adequacy of the methods that are used to diagnose the metabolic syndrome are described. Urbanization, environmental pollution, tobacco smoking and many other factors have led to an increase in the number of patients with combined cardiovascular and respiratory system diseases, in particular such as chronic obstructive illness and hypertension. The purpose of the study was to substantiate the expediency of using methods of diagnosis of insulin resistance, estimation of the obesity degree, level of blood pressure and lipid spectrum of blood, and the rheological properties of blood in patients with combined cardiovascular and respiratory system pathology. The role of diet therapy, physical exercises, and drug and non-drug measures in the prevention of a metabolic syndrome associated with chronic obstructive pulmonary disease is shown. Results and discussion. The results of studies showed that low-calorie diet, as well as the omega-3 polyunsaturated fatty acids had influence on the course of IHD and the atherosclerosis. Diet therapy should be aimed at reducing the total caloric content by 20%, but not less than 1200 kcal / day. It is recommended to balance the diet on the main components: proteins – 15%, fats – 30%, carbohydrates – 55-60% of the total. Compliance of the diet should be combined with an increase in physical activity, which plays an important role in reducing the weight of the body, and in maintaining it at an optimal level. The use of pharmacological measures to prevent complications in patients with metabolic syndrome, combined with chronic obstructive pulmonary disease, requires a number of provisions: positive effect or absence of negative influence on the sensitivity of tissues to insulin, glucose, lipid blood spectrum, systemic fibrinolysis, blood pressure level, rheological blood properties. The results of treatment in patients with chronic obstructive pulmonary disease depended on the use of antibiotics, bronchodilators, ambroxol and systemic enzymotherapy. In chronic obstructive pulmonary disease combined with hypertension, special attention was paid to bronchodilators and speleotherapy. Conclusions. Particular importance in the prevention of a metabolic syndrome, combined with chronic obstructive pulmonary disease, acquires the systematic reporting of information on this problem to the population. Primary health care workers should have ongoing preventive work both in healthy patients and in patients with obesity. Mass media, voluntary associations, and food industry workers should and can play a significant role in this.

Keywords: metabolic syndrome, diagnosis, prevention, chronic obstructive pulmonary disease

Full text: PDF (Ukr) 249K

References
  1. Bryukhanova TO. Biokhimichni zminy v orhanizmi tvaryn za zastosuvannya preparativ patohenetychnoi terapiyi metabolichnoho syndromu. Abstr. PhDr. (Biol.). Rubizhne; 2016. 24 p. [Ukrainian]
  2. Onopchenko OV, Kosyakova HV, Horidko TM, Klimashevskyi VM, Hula NM. Vplyv N-stearoiletanolaminu na fosfolipidnyi sklad pechinky shchuriv z insulinorezystentnistyu, sprychynenoyu alimentarnym ozhyrinnyam. Ukrainskyi biokhimichnyi zhurnal. 2014; 86(1): 101–10. [Ukrainian] https://doi.org/ 10.15407/ubj86.01.101
  3. Gumenyuk NN, Lishnevskaya VYu. Vliyanie reosorbilakta na reologicheskie svoystva krovi u bolnykh ishemicheskoy boleznyu serdtsa i khronicheskom obstruktivnom bronkhite. Ukrayinskiy pulmonologichniy zhurnal. 2003; 3: 38–40. [Russian]
  4. Zavgorodnyaya NG, Mikhalchik SV. Korrektsiya metabolicheskikh narusheniy v lechenii i profilaktike u bolnykh insulinnezavisimym sakharnym diabetom. Svit meditsini ta biologiyi. 2017; 4(62): 36-40. [Russian]
  5. Zahayko AL, Voronina LM, Strelchenko KV. Metabolichnyi syndrom: mekhanizmy rozvytku ta perspektyvy antyoksydantnoi terapiyi. Kharkiv: Vyd-vo “Zoloti storinky ”; 2007. 216 p. [Ukrainian]
  6. Kaydashev IP. Evolyutsiya ponyatiya «metabolicheskiy sindrom» i ego sovremennoe znachenie. Ukr med chasopis. 2012; 2: 157-60. [Russian]
  7. Kostina VM, Zyuzin VO, Zinchenko TM. Metabolichnyi syndrom: metody diahnostyky ta reabilitatsiyi. Naukovi pratsi: naukovo-metodychnyi zhurnal. Ekolohiya. Mykolaiv, Vyd-vo ChDU im Petra Mohyly. 2011; 140(152): 76-8. [Ukrainian]
  8. Lyashenko LI, Kostenko VO. NF-κB-oposeredkovanyi vplyv NO-syntaz na vilnoradykalni protsesy u tkanynakh parodonta za umov eksperymentalnoho metabolichnoho syndromu. Aktualni problemy suchasnoi medytsyny: Visn Ukrainskoi med stomat akademiyi. 2014; 14(46): 140-4. [Ukrainian]
  9. Prystupa LN, Dudchenko IO. Vplyv polimorfizmu heniv Β1-adrenoretseptorivta Α-subodynytsi G-bilka na ryzyk rozvytku alimentarnoho ozhyrinnya (ohlyad literatury). Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen. 2013; 1(3): 7. [Ukrainian]
  10. Mitchenko OI. Patohenetychni osnovy metabolichnoho syndromu. Nova medytsyna: Metabolichnyi syndrom. 2004; 3(14): 20-4. [Ukrainian]
  11. Perederiy VM. Ozhirenie: mezhdistsiplinarnyy vyzov meditsine XXI veka. Zdorov’ya Ukrayini. 2010; 10(239): 22-3. [Russian]
  12. Romanov VYu. Syndrom insulinorezystentnosti pry hipotyreozi: osoblyvosti formuvannya likuvannya. Nova medytsyna: Metabolichnyi syndrom. 2004; 3(14): 44-7. [Ukrainian]
  13. Smyrnova IP. Ozhyrinnya. Nova medytsyna: Metabolichnyi syndrom. 2004; 3(14): 17-9. [Ukrainian]
  14. Feshchenko Yu, Gavrilyuk V. Khronicheskie obstruktivnye zabolevaniya legkikh: klassifikatsiya, diagnostika, lechenie (chast 1). Liki Ukrayini. 2004; 9: 14–7. [Russian]
  15. Chazova NE, Mychka VB, Belenkov YuN. Effektivnost primeneniya akarbozy u patsientov s narushennoy tolerantnostyu k glyukoze i arterialnoy gipertenziey. Ozhirenie i metabolizm. 2005; 1(9): 13-21. [Russian] https://doi.org/10.14341/2071-8713-4799
  16. Damasceno DC, Netto AO, Iessi IL, Gallego FQ, Corvino SB, Dallaqua B, et al. Streptozotocin-induced diabetes models: pathophysiological mechanisms and fetal outcomes. BioMed Research International. 2014; 2014: 819065. https://www.ncbi.nlm.nih.gov/pubmed/24977161. https://www.ncbi.nlm.nih.gov/pmc/articles/4058231. https://doi.org/10.1155/2014/819065
  17. de Arriba A, Domínguez M, Labarta JI, Domínguez M, Puga B, Mayayo E, et al. Metabolic syndrome and endothelial dysfunction in a population born small for gestational age relationship to growth and Gh herapy. Pediatr Endocrinol Rev. 2013; 10(3): 297-307. https://www.ncbi.nlm.nih.gov/pubmed/23724437
  18. International Diabetes Federation. Diabetes Atlas. 6th edition. Brussels Belgium: International Diabetes Federation; 2013. 160 p.
  19. Jurgoński A, Juśkiewicz J, Zduńczyk Z. A high-fat diet differentially affects the gut metabolism and blood lipids of rats depending on the type of dietary fat and carbohydrate. Nutrients. 2014; 6(2): 616-26. https://doi.org/10.3390/nu6020616